Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1351586

registered interest
date	18/08/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Intellectual Property: Writers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, if his Department will take steps to ensure that the concerns of authors are included in his Department’s work on the UK’s future regime for the exhaustion of intellectual property rights, after the closure of the current open consultation.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	40897
answer	answer is ministerial correction date of answer 09/09/2021 answer text <p>Officials at the Intellectual Property Office (an executive agency of the Department for Business, Energy and Industrial Strategy), which is responsible for policy development on the UK’s IP exhaustion regime have met with representatives of the UK book industry, including authors, to discuss the issues arising from this open consultation.</p> answering member constituency Derby North answering member printed Amanda Solloway question first answered 09/09/2021 13:53:46 answering member 4372 label Biography information for Amanda Solloway
tabling member	4079 label Biography information for Julian Sturdy

1351587

registered interest
date	18/08/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Intellectual Property: Writers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what recent representations his Department has received from (a) members of the public and (b) the publishing sector on the save our books campaign; and if he will make an assessment of the implications for his policies of those representations.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	40898
answer	answer is ministerial correction date of answer 09/09/2021 answer text <p>The Department for Business, Energy and Industrial Strategy is currently consulting on the UK’s future exhaustion of IP rights regime and has received responses from a variety of respondents.</p><p> </p><p>The consultation on this matter is still ongoing and once the consultation has closed, the Department will assess information arising from that consultation so that a decision may be made.</p> answering member constituency Derby North answering member printed Amanda Solloway question first answered 09/09/2021 12:26:42 answering member 4372 label Biography information for Amanda Solloway
tabling member	4079 label Biography information for Julian Sturdy

1351588

registered interest
date	18/08/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Intellectual Property: Writers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, with reference to the consultation entitled the UK’s future exhaustion of intellectual property rights regime, published by the Intellectual Property Office on 21 July 2021, what impact assessment his Department has conducted of the potential effect on the (a) UK publishing industry and (b) UK authors of the potential introduction of an international exhaustion framework for copyright.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	40899
answer	answer is ministerial correction date of answer 09/09/2021 answer text <p>The consultation on the UK’s future exhaustion of intellectual property rights regime is open and the Government welcomes all interested parties to contribute to the consultation prior to the closing date of 31 August. An impact assessment was published alongside the consultation which will be updated.</p> answering member constituency Derby North answering member printed Amanda Solloway question first answered 09/09/2021 12:25:03 answering member 4372 label Biography information for Amanda Solloway
tabling member	4079 label Biography information for Julian Sturdy

1328965

registered interest
date	27/05/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Animal Free Research UK
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps his Department is taking to engage with the work of Animal Free Research UK on reducing the use of animals in medical research.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	8592
answer	answer is ministerial correction date of answer 10/06/2021 answer text <p>Animal Free Research UK have recently shared their report: ‘Modernising Medical Research: How Britain can become a global leader in animal free science’.</p><p>We are already taking steps to replace, reduce and refine the use of animals in research. This is an area that is carefully regulated and one that remains important in ensuring new medicines and treatments are safe. The Government believes that animals should only be used when there is no practicable alternative and it actively supports and funds the development and dissemination of techniques that replace, reduce and refine the use of animals in research (the 3Rs). This is achieved primarily through funding for the National Centre for the 3Rs, which works nationally and internationally to drive the uptake of 3Rs technologies and ensure that advances in the 3Rs are reflected in policy, practice and regulations on animal research.</p><p>Since the NC3Rs was launched it has committed £100 million through its research, innovation, and early career awards to provide new 3Rs approaches for scientists in academia and industry to use.</p> answering member constituency Derby North answering member printed Amanda Solloway question first answered 10/06/2021 07:48:52 answering member 4372 label Biography information for Amanda Solloway
tabling member	4079 label Biography information for Julian Sturdy

1308236

registered interest
date	12/04/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Animal Experiments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps his Department is taking to reduce the use of animals in scientific experiments through promoting investment in human-relevant life sciences.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	179096
answer	answer is ministerial correction date of answer 20/04/2021 answer text <p>The use of animals in research is carefully regulated and remains important in ensuring new medicines and treatments are safe.   At the same time, the Government believes that animals should only be used when there is no practicable alternative and it actively supports and funds the development and dissemination of techniques that replace, reduce and refine the use of animals in research (the 3Rs).  This is achieved primarily through funding for the National Centre for the 3Rs, which works nationally and internationally to drive the uptake of 3Rs technologies and ensure that advances in the 3Rs are reflected in policy, practice and regulations on animal research.  Across the UK, the NC3Rs has invested £71 million in research through grants to universities, and almost £28 million in contracts through its CRACK IT Challenges innovation scheme to UK and EU-based institutions, mainly focusing on new approaches for the safety assessment of pharmaceuticals and chemicals that reduce the use of animals.</p><p> </p><p>UK Research and Innovation (UKRI) funds a portfolio of research projects involving humans, human materials, animal models, and non-animal technologies. At this time, no artificial model or simulation can replicate the complexity of disease processes in a living organism and as such, whole organism approaches continue to be important; animal models are used when experimentation in human volunteers is not possible for safety or ethical reasons. However, we do recognise the increasing value of <em>in vitro</em> and <em>in silico</em> models, including organs-on-chips and 3-dimensional mini-brains, which can greatly aid the development of new healthcare innovations and also reduce, refine or replace the use of animals in research.</p><p /><p>The Medical Research Council (MRC), part of UKRI, has for a number of years prioritised experimental medicine research, in which studies are undertaken in humans to identify disease mechanisms and provide early evidence and validity of new discoveries or treatments. In order to accelerate progress in this area a vision for a new Precision Medicine Accelerator (PMA) was approved by MRC in December 2019. The first step of the PMA, a new Experimental Medicine Panel, has been launched to fund academic-led, interventional clinical studies in humans.</p> answering member constituency Derby North answering member printed Amanda Solloway question first answered 20/04/2021 16:59:25 answering member 4372 label Biography information for Amanda Solloway
tabling member	4079 label Biography information for Julian Sturdy

1204792

registered interest
date	17/06/2020
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Clinical Trials: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what proportion of the core science budget was allocated to fund medical trials of new drugs during the last period for which data is available.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	60748
answer	answer is ministerial correction date of answer 24/06/2020 answer text <p>UK Research and Innovation is funded by the Department for Business, Energy and Industrial Strategy and supports basic research into the development of new drugs including pre-clinical research and early stage clinical trials. It does not routinely analyse data on the number of trials specifically relating to the development of new drugs.</p><p> </p><p>UK Research and Innovation supports clinical trials through the Medical Research Council (MRC) including early phase clinical stage trials through ‘response mode’ schemes such as the Developmental Pathway Funding Scheme, which supports pre-clinical development and early clinical trial of novel therapeutics including new and repurposing of existing therapies.</p><p> </p><p>Later stage trials are funded through the Efficacy and Mechanism Evaluation Programme (which is a jointly funded partnership between MRC and the National Institute for Health Research). The MRC also supports:</p><p> </p><ul><li>The Joint Global Health Trials programme in partnership with the National Institute for Health Research, the Department for International Development and the Wellcome Trust.</li><li>The European Developing Countries Clinical Trials programme (EDCTP), with a specific focus on poverty-related infectious diseases in Sub-Saharan Africa.</li></ul><p> </p><p>These provide funding to later stage trials including studies evaluating the efficacy and effectiveness of interventions with potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care.</p><p> </p><p>A recent example of a clinical trial project for a new medicine is the award of over £2.7 million for a Clinical Trial of a Novel Treatment for <em>Clostridium difficile (</em>associated diarrhoea) from Innovate UK as part of the Biomedical Catalyst. This was awarded to MGB Biopharma Ltd based in Glasgow for this new class of small molecule antibiotic.</p> answering member constituency Derby North answering member printed Amanda Solloway question first answered 24/06/2020 14:43:42 answering member 4372 label Biography information for Amanda Solloway
tabling member	4079 label Biography information for Julian Sturdy